| |
Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems
|
| |
| |
Download the PDF here
AIDS: Jan 2 2014
"In this large, multicentre cohort of HIV-infected men, the TRT initiation rate (19.7/1000 person-years) was over 2.5 times higher than that reported from insurance claims for US adult men in 2011 (7.57/1000 person-years)......evidence for pre-TRT testosterone deficiency was lacking in 76%
.......In conclusion, HIV-infected men initiate TRT at high rates, potentially without baseline testosterone deficiency or recommended posttreatment monitoring. Overuse of TRT can increase the risks of erythrocytosis, metastatic prostate cancer, reduced sperm production and infertility [3]. Further, TRT has been associated with myocardial infarction in those with preexisting cardiovascular disease [9], which may be conferred by HIV infection itself [20,21]. TRT data capture and reporting should be prioritized in HIV research agendas, and subsequent studies will evaluate outcomes and causes of TRT in HIV-infected men."
Bhatia, Ramonaa; Murphy, Adam B.b; Raper, James L.c; Chamie, Gabrield; Kitahata, Mari M.e; Drozd, Daniel R.e; Mayer, Kennethf; Napravnik, Soniag; Moore, Richardh; Achenbach, Chadi
aInstitute for Public Health and Medicine, Northwestern University, ChicagobDepartment of Urology, Northwestern University, Chicago, IllinoiscDepartment of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AlabamadDivision of HIV/AIDS, San Francisco General Hospital, University of California, San Francisco, CaliforniaeDepartment of Medicine, Division of Allergy & Infectious Diseases, University of Washington, Seattle, WashingtonfDepartment of Global Health and Population, Fenway Community Health Center of Harvard University, Boston, MassachusettsgDepartment of Medicine, Division of Infectious Diseases, University of North Carolina, Chapel Hill, North CarolinahDivision of Infectious Diseases, Johns Hopkins University, Baltimore, MarylandiDepartment of Medicine, Division of Infectious Diseases, Northwestern University, Chicago, Illinois, USA.
Abstract
Objective:
The objectives of this study were to determine the rate of testosterone replacement therapy (TRT) initiation, TRT predictors and associated monitoring in HIV-infected men.
Design:
A multisite cohort study.
Methods:
We examined TRT initiation rates and monitoring among adult HIV-infected men in routine care at seven sites in the Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) from 1996 to 2011. We determined TRT predictors using Cox regression modelling.
Results:
Of 14 454 men meeting inclusion criteria, TRT was initiated in 1482 (10%) with an initiation rate of 19.7/1000 person-years [95% confidence interval (95% CI) 18.7-20.7]. In the multivariable model, TRT was significantly associated with age at least 35 years, white race, diagnosis of AIDS wasting, hepatitis C coinfection, protease inhibitor based antiretroviral therapy and nadir CD4+ cell count of 200 cells/μl or less. Overall, 1886 out of 14 454 (13%) had testosterone deficiency. Among those initiating TRT, 992 out of 1482 (67%) had a pre-TRT serum total testosterone measured, and deficiency [<300 ng/dl (10.4 nmol/l)] was found in 360 out of 1482 (24%). Post-TRT serum total testosterone was measured within 6 months of TRT initiation in 377 out of 1482 (25%) men.
Conclusion:
TRT was common in HIV-infected men, though evidence for pre-TRT testosterone deficiency was lacking in 76%. Endocrine guidelines for post-TRT monitoring were uncommonly followed. Given cardiovascular and other risks associated with TRT, efforts should focus on understanding factors driving these TRT practices in HIV-infected men.
Background
Global testosterone sales have increased 12-fold over the last decade, and the USA is the second leading consumer worldwide [1]. Androgen use tripled from 2001 to 2011 in the U.S., with 2.9% of men over 40 years of age on testosterone replacement therapy (TRT) [2]. Establishing biochemical testosterone deficiency is recommended before TRT initiation [3], yet up to 83% of men on TRT lack pretreatment testosterone measurements [4]. Direct-to-consumer marketing and the availability of specialty clinics and transdermal preparations may contribute to TRT overuse in the USA [1,5,6]. This is concerning in light of recent studies suggesting that TRT may increase the risk of cardiovascular events [7,8], including myocardial infarction [9,10], stroke [10], thrombosis [11] and death [10], though these remain areas of ongoing investigation.
HIV is associated with testosterone deficiency [12] in up to 70% of men, a finding that persists despite successful antiretroviral therapy (ART) [13], and hypogonadism is expected to increase, as this population continues to age [14]. Yet, little is known about TRT among HIV-infected men. In a report from the early ART-era, TRT prevalence was 19%, though pre-TRT testosterone deficiency and post-TRT monitoring were not assessed [15]. In this report, we describe TRT initiation rates and predictors and associated monitoring among HIV-infected men in a large, multicentre U.S. cohort.
Materials and methods
The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) electronically collects and standardizes socio-demographic, clinical, laboratory and medication data from inpatient and outpatient encounters of over 28 000 HIV-infected individuals at eight US sites [16]. We performed a cohort study of adult HIV-infected men seen at one of the seven CNICS clinical sites in which TRT data were available from 1996 to 2011. We excluded men on TRT prior to or within 30 days after cohort entry or with unknown TRT initiation date. TRT initiation was determined on the basis of documentation of transdermal (gel, patch or solution), intramuscular (testosterone cypionate or enanthate), oral or implantable formulations in pharmacy dispensing records, electronic medical records and/or chart abstractions. We defined testosterone deficiency as serum total testosterone less than 300 ng/dl (10.4 nmol/l) based on US endocrinology practice guidelines [3]. Comorbidities were documented by the providers in the medical record.
We calculated TRT initiation rate as the number of TRT initiation events per person-years of follow-up time from cohort entry to initial TRT date, loss to follow-up or death. We assessed predictors of TRT initiation with univariable and multivariable Cox regression modelling. Statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, North Carolina, USA). This study was approved by the Northwestern University Institutional Review Board.
Results
There were 14 454 men without evidence of TRT prior to CNICS entry with 75 173 person-years of follow-up time (Table 1). TRT was initiated in 1482 (10%) men at a median age of 44 [interquartile range (IQR) 38-51] years. The median time between cohort enrolment and TRT initiation was 868 days (IQR 280-1907). Two TRT preparations were initiated on the same day for 102 men. Of the 1584 incident medications, 624 (39%) were intramuscular, 503 (32%) were transdermal, one (0.1%) was oral and 456 (29%) were unspecified.
We calculated a TRT initiation rate of 19.7/1000 person-years [95% confidence interval (95% CI) 18.7-20.7]. Higher rates of TRT initiation were associated with age at least 35 years, white race, MSM HIV risk factor, diagnosis of AIDS wasting, protease inhibitor based ART, nadir CD4+ T-lymphocyte cell count (CD4+) of 200 cells/μl or less, nonsmoking and absence of alcohol abuse.
In a multivariable model including all variables in the Table 1 and CNICS site, TRT initiation was independently associated with age at least 35 years, white race, diagnosis of AIDS wasting, hepatitis C coinfection, protease inhibitor-based ART and nadir CD4+ cell count of 200 cells/μl or less (Table 1).
During cohort follow-up, 6168 of 14 454 (43%) men had at least one serum total testosterone measurement, and 1886 of 6168 (31%) had testosterone deficiency. Of the men with testosterone deficiency, 1119 (59%) did not initiate TRT.
Among the 1482 men initiating TRT, pre-TRT serum total testosterone level was measured in 992 (67%), with a median average pretreatment level of 358 (IQR 248-499) ng/dl [12.4 (IQR 8.6-17.3) nmol/l]. Pre-TRT testosterone deficiency was found in 360 (24%). Serum total testosterone was measured at least once after TRT initiation in 898 (61%), with a median maximum post-TRT level of 569 (IQR 370-841) ng/dl [19.7 (IQR 12.8-29.2) nmol/l]. Median time to first post-TRT serum total testosterone measurement was 303 (IQR 104-885) days. The first post-TRT serum total testosterone measurement occurred within 6 months of TRT initiation in 377 (25%) men.
Over half (55%, 812/1482) of those initiating TRT were over age 40. In this group, 273 (34%) and 97 (12%) had pre and 6-month post-TRT prostate-specific antigen (PSA) measurements, respectively.
Discussion
In this large, multicentre cohort of HIV-infected men, the TRT initiation rate (19.7/1000 person-years) was over 2.5 times higher than that reported from insurance claims for US adult men in 2011 (7.57/1000 person-years) [5].
Endocrine Society Clinical Practice Guidelines [3] state that TRT is indicated for symptomatic men with unequivocal biochemical androgen deficiency. In one-third (490/1482) of men initiating TRT in CNICS, pre-TRT serum total testosterone levels were unavailable or unmeasured. Only 360 of 1482 (24%) men initiating TRT had laboratory-confirmed testosterone deficiency [serum total testosterone <300 ng/dl (10.4 nmol/l)], similar to rates from general male populations initiating TRT (12-40%) [5]. Further, only 273 of 812 (34%) men over age 40 for whom pre-TRT PSA levels are recommended [3] underwent PSA testing, consistent with other reports (34.9% [4]). These data suggest that TRT may be commonly administered to HIV-infected men without adequate baseline laboratory evaluation and establishment of recommended indications.
We propose several reasons for higher TRT initiation rates among HIV-infected men. Symptomatology associated with hypogonadism, such as fatigue, psychosexual dysfunction and erectile dysfunction [2], may occur more commonly in HIV-infected men and prompt empiric TRT. HIV-infected men may also have greater opportunity to be offered TRT during frequent provider visits. In addition, AIDS wasting and low nadir CD4+ cell count, proxies for end-stage AIDS, predicted TRT in our study. TRT is indicated for HIV-infected men with low testosterone and AIDS-associated weight loss [3]; however, only 4% ever had AIDS wasting, suggesting that this was not a major contributor. Finally, protease inhibitor use was associated with TRT. Older protease inhibitor based ART is implicated in lipodystrophy and fat redistribution. Body morphologic changes associated with lipodystrophy can be similar to those of testosterone deficiency and may lead to TRT. Protease inhibitors may also enhance peripheral conversion of testosterone to estradiol, resulting in symptoms of hypogonadism [12].
We found inadequate post-TRT monitoring. Endocrinology guidelines recommend monitoring serum testosterone levels 3-6 months after TRT initiation [3], yet these measurements were lacking in 39% and obtained within the first 6 months in only 25% of men. Although some patients may have declined testing or received testing outside CNICS, these findings strongly suggest that that HIV providers may not follow recommended monitoring guidelines.
CNICS is limited by the ability to consistently capture data on serum testosterone and PSA testing and TRT obtained from providers outside clinical sites, potentially leading to underreporting of pre-TRT deficiency, post-TRT monitoring and/or TRT initiation. This could partially explain the high proportion (59%) of men with biochemical testosterone deficiency in the cohort who did not appear to initiate TRT. In addition, it is possible that alternative diagnostic tests were used for determining pre-TRT testosterone deficiency and post-TRT monitoring. Elevations in sex-hormone binding globulin (SHBG) in HIV-infected men may result in low serum-free (bioavailable) testosterone but seemingly normal serum total testosterone [17,18], prompting some to utilize serum-free testosterone to screen for deficiency and/or monitor response to TRT in men with HIV [19]. Serum-free testosterone and SHBG laboratory data are inconsistently captured in CNICS and were not utilized for these analyses, which could have contributed to low observed rates of pre-TRT testosterone deficiency and post-TRT testosterone monitoring. We are also unable to verify whether serum testosterone measurements were obtained as recommended in the morning, when levels are most predictable [3]. Finally, due to data limitations, we cannot comment on symptoms, other patient factors or provider factors driving these TRT practices. The strength of our study is comprehensive laboratory, clinical and medication data from a large and geographically diverse cohort reflecting routine care of HIV-infected men in the USA.
In conclusion, HIV-infected men initiate TRT at high rates, potentially without baseline testosterone deficiency or recommended posttreatment monitoring. Overuse of TRT can increase the risks of erythrocytosis, metastatic prostate cancer, reduced sperm production and infertility [3]. Further, TRT has been associated with myocardial infarction in those with preexisting cardiovascular disease [9], which may be conferred by HIV infection itself [20,21]. TRT data capture and reporting should be prioritized in HIV research agendas, and subsequent studies will evaluate outcomes and causes of TRT in HIV-infected men.
|
|
| |
| |
|
|
|
